GlassScriptPhysician profile
Spencer F Johnson
NPI 1063579779
$3,439.99
in general payments reported to CMS, 2019-2025
14 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $26.53 · 2021: $291 · 2022: $322 · 2023: $181 · 2024: $783 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.46 |
| Education | $135.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $980.92 | 2021-2025 | Caplyta |
| Alkermes, INC. | $418.73 | 2019-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $393.47 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $386.57 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $289.02 | 2019-2025 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $248.87 | 2019-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $235.99 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $124.36 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $117.58 | 2019-2025 | Ingrezza |
| Shire North American Group INC | $62.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $55.24 | 2019 | |
| Avanir Pharmaceuticals, INC. | $47.39 | 2019 | |
| Sunovion Pharmaceuticals INC. | $44.19 | 2019 | |
| Allergan, INC. | $35.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.